Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Zero-shot prediction of therapeutic use with geometric deep learning and clinician centered design

View ORCID ProfileKexin Huang, View ORCID ProfilePayal Chandak, View ORCID ProfileQianwen Wang, View ORCID ProfileShreyas Havaldar, View ORCID ProfileAkhil Vaid, View ORCID ProfileJure Leskovec, View ORCID ProfileGirish Nadkarni, View ORCID ProfileBenjamin S. Glicksberg, View ORCID ProfileNils Gehlenborg, View ORCID ProfileMarinka Zitnik
doi: https://doi.org/10.1101/2023.03.19.23287458
Kexin Huang
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kexin Huang
Payal Chandak
2Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Payal Chandak
Qianwen Wang
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qianwen Wang
Shreyas Havaldar
3Hasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shreyas Havaldar
Akhil Vaid
3Hasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029
4Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Akhil Vaid
Jure Leskovec
5Department of Computer Science, Stanford University, Stanford, CA 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jure Leskovec
Girish Nadkarni
4Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Girish Nadkarni
Benjamin S. Glicksberg
3Hasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029
4Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin S. Glicksberg
Nils Gehlenborg
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nils Gehlenborg
Marinka Zitnik
1Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115
6Broad Institute of MIT and Harvard, Cambridge, MA 02142
7Harvard Data Science Initiative, Cambridge, MA 02138
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marinka Zitnik
  • For correspondence: marinka{at}hms.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Of the several thousand diseases that affect humans, only about 500 have treatments approved by the U.S. Food and Drug Administration. Even for those with approved treatments, discovering new drugs can offer alternative options that cause fewer side effects and replace drugs that are ineffective for certain patient groups. However, identifying new therapeutic opportunities for diseases with limited treatment options remains a challenge, as existing algorithms often perform poorly. Here, we leverage recent advances in geometric deep learning and human-centered AI to introduce TXGNN, a model for identifying therapeutic opportunities for diseases with limited treatment options and minimal molecular understanding. TXGNN is a graph neural network pre-trained on a comprehensive knowledge graph of 17,080 clinically-recognized diseases and 7,957 therapeutic candidates. The model can process various therapeutic tasks, such as indication and contraindication prediction, in a unified formulation. Once trained, we show that TXGNN can perform zero-shot inference on new diseases without additional parameters or fine-tuning on ground truth labels. Evaluation of TXGNN shows significant improvements over existing methods, with up to 49.2% higher accuracy in indication tasks and 35.1% higher accuracy in contraindication tasks. TXGNN can also predict therapeutic use for new drugs developed since June 2021. To facilitate interpretation and analysis of the model’s predictions by clinicians, we develop a human-AI explorer for TXGNN and evaluate its usability with medical experts. Finally, we demonstrate that TXGNN’s novel predictions are consistent with off-label prescription decisions made by clinicians in a large healthcare system. These label-efficient and clinician-centered learning systems pave the way for improvements for many therapeutic tasks.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

K.H., P.C., and M.Z. gratefully acknowledge the support by NSF under No.~IIS-2030459, US Air Force under No.~FA8702-15-D-0001, and awards from Harvard Data Science Initiative, Amazon Research, Bayer Early Excellence in Science, AstraZeneca Research, and Roche Alliance with Distinguished Scientists. P.C. was supported, in part, by the Harvard Summer Institute in Biomedical Informatics. Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the funders.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All clinical and electronic medical record data were deidentified, and the Institutional Review Board at Mount Sinai, New York City, U.S., approved the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The TxGNN's project website is at https://zitniklab.hms.harvard.edu/projects/TxGNN. Therapeutics-centered knowledge graph is available at https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/IXA7BM under a persistent identifier https://doi.org/10.7910/DVN/IXA7BM. We have deposited the knowledge graph and all relevant intermediate files in this repository. Python implementation of the methodology developed and used in the study is available via the project website at https://zitniklab.hms.harvard.edu/projects/TxGNN. The code to reproduce results, documentation, and usage examples are at https://github.com/mims-harvard/TxGNN. To facilitate the usage of the algorithm, we developed a TxGNN Explorer, a web-based app available at http://txgnn.org to access TxGNN's predictions.

https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/IXA7BM

https://zitniklab.hms.harvard.edu/projects/TxGNN

http://txgnn.org

https://github.com/mims-harvard/TxGNN

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 20, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Zero-shot prediction of therapeutic use with geometric deep learning and clinician centered design
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Zero-shot prediction of therapeutic use with geometric deep learning and clinician centered design
Kexin Huang, Payal Chandak, Qianwen Wang, Shreyas Havaldar, Akhil Vaid, Jure Leskovec, Girish Nadkarni, Benjamin S. Glicksberg, Nils Gehlenborg, Marinka Zitnik
medRxiv 2023.03.19.23287458; doi: https://doi.org/10.1101/2023.03.19.23287458
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Zero-shot prediction of therapeutic use with geometric deep learning and clinician centered design
Kexin Huang, Payal Chandak, Qianwen Wang, Shreyas Havaldar, Akhil Vaid, Jure Leskovec, Girish Nadkarni, Benjamin S. Glicksberg, Nils Gehlenborg, Marinka Zitnik
medRxiv 2023.03.19.23287458; doi: https://doi.org/10.1101/2023.03.19.23287458

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (428)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (362)
  • Dermatology (276)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1168)
  • Epidemiology (13349)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5140)
  • Geriatric Medicine (481)
  • Health Economics (781)
  • Health Informatics (3261)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4914)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4198)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (496)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)